Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Biocept nets $8.7mm through private stock sale

Executive Summary

Biocept Inc. (blood-based molecular diagnostics for solid tumors) netted $8.7mm through the sale of 4.3mm common shares at $2.15 (a slight discount) to institutional investors. The placement included five-year warrants to buy another 2.16mm shares at $2.50. Roth Capital Partners, WestPark Capital, and Chardan Capital were the placement agents.
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Laboratory Testing Services
  • Services
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies